Reduction in Plasmodium falciparum Pfk13 and pfg377 allele diversity through time in southern Vietnam.
Artemisinin resistance
Gametocyte
K13-propeller gene
Plasmodium falciparum
Vietnam
pfg377 gene
Journal
Tropical medicine and health
ISSN: 1348-8945
Titre abrégé: Trop Med Health
Pays: Japan
ID NLM: 101215093
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
received:
29
11
2021
accepted:
20
02
2022
entrez:
2
3
2022
pubmed:
3
3
2022
medline:
3
3
2022
Statut:
epublish
Résumé
Plasmodium falciparum has acquired resistance to artemisinin in Southeast Asia, with mutations in the P. falciparum Kelch-13 (Pfk13) gene associated with the resistance phenotype. The widespread use of Artemisinin-based combination therapy (ACT)s in Southeast Asia has led to the selection and spread of parasites carrying mutations in Pfk13. We characterised the allele diversity of Pfk13 and pfg377, an artemisinin-resistance neutral polymorphic gene, in parasite DNA extracted human blood from in southern Vietnam in 2003, 2012, 2015 and 2018. This study was conducted in Bu Gia Map commune, Binh Phuoc province, Vietnam, from May 2018 to January 2019. Twenty-four samples from 2018 to 2019, 30 from 2003, 24 from 2012 and 32 from 2015 were analysed. Malaria-infected human blood was collected by finger-prick and used for molecular analysis. A nested-PCR targeting the small subunit ribosomal RNA gene was used for Plasmodium species identification, followed by amplification and nucleotide sequencing of Pfk13 and region 3 of pfg377. Archived blood samples collected in the same region in 2012 and 2015 were also analysed as above for comparison. The genetic diversity of Pfk13 and pfg377 was lower in 2018-2019 compared to 2012 and 2015. The number of distinct Pfk13 mutants decreased from three in 2012 and 2015, P553L, V568G and C580Y, to one, C580Y in 2018-2019. In 2018-2019, the frequency of C580Y mutant strains was 71% (17/24 isolates). All samples were wild type in 2003. In 2012 and 2015, there were single-strain infections as well as co-infections with two mutant strains or with mutant and wild strains, whereas there were no co-infections in 2018. pfg377 allele diversity decreased from five alleles in 2012 to two alleles in 2018-2019. The genetic diversity of P. falciparum was reduced at the two genetic loci surveyed in this study, Pfk13 and pfg377. In the case of the former gene, we observed an increase in the prevalence of parasites carrying the C580Y gene, known to confer reduced susceptibility to ACTs. The reduction in the diversity of pfg377 may be linked to the clonal expansion of parasite strains carrying the C580Y mutation, leading to an overall reduction in parasite genetic diversity across the population.
Sections du résumé
BACKGROUND
BACKGROUND
Plasmodium falciparum has acquired resistance to artemisinin in Southeast Asia, with mutations in the P. falciparum Kelch-13 (Pfk13) gene associated with the resistance phenotype. The widespread use of Artemisinin-based combination therapy (ACT)s in Southeast Asia has led to the selection and spread of parasites carrying mutations in Pfk13. We characterised the allele diversity of Pfk13 and pfg377, an artemisinin-resistance neutral polymorphic gene, in parasite DNA extracted human blood from in southern Vietnam in 2003, 2012, 2015 and 2018.
METHOD
METHODS
This study was conducted in Bu Gia Map commune, Binh Phuoc province, Vietnam, from May 2018 to January 2019. Twenty-four samples from 2018 to 2019, 30 from 2003, 24 from 2012 and 32 from 2015 were analysed. Malaria-infected human blood was collected by finger-prick and used for molecular analysis. A nested-PCR targeting the small subunit ribosomal RNA gene was used for Plasmodium species identification, followed by amplification and nucleotide sequencing of Pfk13 and region 3 of pfg377. Archived blood samples collected in the same region in 2012 and 2015 were also analysed as above for comparison.
RESULTS
RESULTS
The genetic diversity of Pfk13 and pfg377 was lower in 2018-2019 compared to 2012 and 2015. The number of distinct Pfk13 mutants decreased from three in 2012 and 2015, P553L, V568G and C580Y, to one, C580Y in 2018-2019. In 2018-2019, the frequency of C580Y mutant strains was 71% (17/24 isolates). All samples were wild type in 2003. In 2012 and 2015, there were single-strain infections as well as co-infections with two mutant strains or with mutant and wild strains, whereas there were no co-infections in 2018. pfg377 allele diversity decreased from five alleles in 2012 to two alleles in 2018-2019.
CONCLUSION
CONCLUSIONS
The genetic diversity of P. falciparum was reduced at the two genetic loci surveyed in this study, Pfk13 and pfg377. In the case of the former gene, we observed an increase in the prevalence of parasites carrying the C580Y gene, known to confer reduced susceptibility to ACTs. The reduction in the diversity of pfg377 may be linked to the clonal expansion of parasite strains carrying the C580Y mutation, leading to an overall reduction in parasite genetic diversity across the population.
Identifiants
pubmed: 35232492
doi: 10.1186/s41182-022-00409-4
pii: 10.1186/s41182-022-00409-4
pmc: PMC8887123
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19Subventions
Organisme : Japan Society for the Promotion of Science
ID : 26360029
Organisme : Japan Society for the Promotion of Science
ID : 17H04513
Organisme : Japan Society for the Promotion of Science
ID : 20H04411
Informations de copyright
© 2022. The Author(s).
Références
Lancet Infect Dis. 2017 Oct;17(10):1022-1023
pubmed: 28948924
PLoS One. 2019 Mar 18;14(3):e0213686
pubmed: 30883571
Mol Biol Evol. 2017 Jan;34(1):131-144
pubmed: 28025270
Antimicrob Agents Chemother. 2017 Mar 24;61(4):
pubmed: 28137815
Antimicrob Agents Chemother. 2018 Aug 27;62(9):
pubmed: 29914963
Exp Parasitol. 2000 Jul;95(3):163-9
pubmed: 10964643
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):240-5
pubmed: 23248304
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
J Infect Dis. 2002 Jun 15;185(12):1838-42
pubmed: 12085337
Parasit Vectors. 2017 Jun 24;10(1):308
pubmed: 28646896
J Infect Dis. 2015 Mar 1;211(5):670-9
pubmed: 25180241
Mol Biochem Parasitol. 1995 Nov;74(2):143-56
pubmed: 8719156
Lancet Infect Dis. 2012 Nov;12(11):851-8
pubmed: 22940027
Clin Microbiol Infect. 2016 Mar;22(3):285.e1-8
pubmed: 26548510
N Engl J Med. 2008 Dec 11;359(24):2619-20
pubmed: 19064625
Lancet. 2012 May 26;379(9830):1960-6
pubmed: 22484134
PLoS One. 2013;8(3):e57689
pubmed: 23520478
Clin Pharmacokinet. 2008;47(2):91-102
pubmed: 18193915
Int J Parasitol. 2009 Dec;39(14):1533-7
pubmed: 19703460
Acta Trop. 2008 Aug;107(2):121-7
pubmed: 18554563
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
Elife. 2016 Mar 04;5:
pubmed: 26943619
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
Trop Med Health. 2019 Jan 23;47:9
pubmed: 30692869
Mol Biochem Parasitol. 2000 Nov;111(1):153-61
pubmed: 11087925